Literature DB >> 7821999

Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis.

J Nemeth1, J C Lee.   

Abstract

The protective efficacy of antibodies to the Staphylococcus aureus capsular polysaccharide was examined in a rat model of catheter-induced endocarditis. Capsular antibodies were induced either by active immunization with killed S. aureus or by passive immunization with hyperimmune rabbit antiserum to S. aureus. Control rats were injected with phosphate-buffered saline or passively immunized with normal rabbit serum or rabbit antiserum to a nonencapsulated strain. Animals with indwelling catheters were challenged intravenously with 5 x 10(4) to 4 x 10(6) CFU of the homologous S. aureus strain (capsular serotype 5 strain Reynolds or serotype 1 strain SA1 mucoid). Both immunized and control rats developed S. aureus endocarditis. The numbers of S. aureus cells recovered from the blood and aortic valve vegetations of immunized rats were similar to those of control rats, indicating that capsule-specific antibodies were not protective. To determine whether the presence of an indwelling catheter interfered with antibody-mediated protection against S. aureus endocarditis, catheters were removed 2 h after insertion in additional groups of rats. An inoculum of 10(8) CFU of strain Reynolds was needed to provoke endocarditis in rats catheterized for 2 h, compared with 5 x 10(4) CFU for rats with indwelling catheters. Passively transferred capsular antibodies were not protective since both immunized and nonimmunized animals developed endocarditis, and quantitative cultures of blood and valvular vegetations revealed no differences between immunized and control animals. The findings of this study indicate that antibodies to the capsular polysaccharide are not protective in the rat model of experimental S. aureus endocarditis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7821999      PMCID: PMC173005          DOI: 10.1128/iai.63.2.375-380.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  A NEW STAPHYLOCOCCAL ANTIGEN. ITS PREPARATION AND IMMUNIZING ACTIVITY AGAINST EXPERIMENTAL INFECTIONS.

Authors:  M W FISHER; H B DEVLIN; A L ERLANDSON
Journal:  Nature       Date:  1963-09-14       Impact factor: 49.962

2.  The extracellualr polysaccharides of bacteria.

Authors:  J F WILKINSON
Journal:  Bacteriol Rev       Date:  1958-03

3.  Adherence of group B streptococci to cultured epithelial cells: roles of environmental factors and bacterial surface components.

Authors:  G S Tamura; J M Kuypers; S Smith; H Raff; C E Rubens
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

4.  Immunogenicity in cows of Staphylococcus aureus type 5 capsular polysaccharide-ovalbumin conjugate.

Authors:  F B Gilbert; B Poutrel; L Sutra
Journal:  Vaccine       Date:  1994-03       Impact factor: 3.641

5.  Staphylococcus aureus microcapsule expression attenuates bacterial virulence in a rat model of experimental endocarditis.

Authors:  L M Baddour; C Lowrance; A Albus; J H Lowrance; S K Anderson; J C Lee
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

6.  Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes.

Authors:  S Xu; R D Arbeit; J C Lee
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

7.  Immunization with fibronectin binding protein from Staphylococcus aureus protects against experimental endocarditis in rats.

Authors:  T Schennings; A Heimdahl; K Coster; J I Flock
Journal:  Microb Pathog       Date:  1993-09       Impact factor: 3.738

8.  Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus.

Authors:  J C Lee; S Takeda; P J Livolsi; L C Paoletti
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A.

Authors:  A Fattom; R Schneerson; D C Watson; W W Karakawa; D Fitzgerald; I Pastan; X Li; J Shiloach; D A Bryla; J B Robbins
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.609

10.  Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate.

Authors:  A Fattom; J Shiloach; D Bryla; D Fitzgerald; I Pastan; W W Karakawa; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.609

View more
  20 in total

1.  Promoter analysis of the cap8 operon, involved in type 8 capsular polysaccharide production in Staphylococcus aureus.

Authors:  S Ouyang; S Sau; C Y Lee
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

2.  Immunization for Prevention of Infective Endocarditis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

3.  Capsule expression by bovine isolates of Staphylococcus aureus from Argentina: genetic and epidemiologic analyses.

Authors:  D O Sordelli; F R Buzzola; M I Gomez; L Steele-Moore; D Berg; E Gentilini; M Catalano; A J Reitz; T Tollersrud; G Denamiel; P Jeric; J C Lee
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  MsaB activates capsule production at the transcription level in Staphylococcus aureus.

Authors:  Justin L Batte; Dhritiman Samanta; Mohamed O Elasri
Journal:  Microbiology       Date:  2016-01-18       Impact factor: 2.777

5.  The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis.

Authors:  I M Nilsson; J C Lee; T Bremell; C Rydén; A Tarkowski
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

6.  Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats.

Authors:  J C Lee; J S Park; S E Shepherd; V Carey; A Fattom
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

7.  MgrA activates expression of capsule genes, but not the α-toxin gene in experimental Staphylococcus aureus endocarditis.

Authors:  Ravi Kr Gupta; Jimena Alba; Yan Q Xiong; Arnold S Bayer; Chia Y Lee
Journal:  J Infect Dis       Date:  2013-07-30       Impact factor: 5.226

8.  Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy.

Authors:  David Skurnik; Andrea Kropec; Damien Roux; Christian Theilacker; Johannes Huebner; Gerald B Pier
Journal:  Clin Infect Dis       Date:  2012-07-17       Impact factor: 9.079

9.  The persistence of biofilm-associated antibiotic resistance of Staphylococcus aureus isolated from clinical bovine mastitis cases in Australia.

Authors:  Charlene Babra; Jully G Tiwari; Gerald Pier; Thi Ha Thein; Raju Sunagar; Srinivasaiah Sundareshan; Shrikrishna Isloor; Nagendra R Hegde; Sharon de Wet; Margaret Deighton; Justine Gibson; Paul Costantino; John Wetherall; Trilochan Mukkur
Journal:  Folia Microbiol (Praha)       Date:  2013-02-28       Impact factor: 2.099

Review 10.  Staphylococcus aureus capsular polysaccharides.

Authors:  Katherine O'Riordan; Jean C Lee
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.